&lt;p&gt;Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles&lt;/p&gt;

Grapa, Cristiana Marian; Mocan, Teodora; Gonciar, Diana; Zdrehuş, Claudiu; Moşteanu, Ofelia; Pop, Teodora; Mocan, Lucian

doi:10.2147/ijn.s226628

Cited by 47 publications

(50 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPPK1 has a potential role in the EGF (epidermal growth factor) signalling pathway as its binds to the EGF receptor [ 78 ]. The participation of EPPK1 in EGF signalling was reported in pancreatic development and carcinogenesis [ 77 , 79 ]. Activation of fluorescent-labelled EPPK1 in HeLa cells, originally of cervical cancer origin [ 29 ], demonstrated dynamic movement of EPPK1 protein, from one side of the cell membrane to another during migration.…”

Section: Plakins In Cancermentioning

confidence: 99%

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

et al. 2021

View full text Add to dashboard Cite

The plakin family of cytoskeletal proteins play an important role in cancer progression yet are under-studied in cancer, especially ovarian cancer. These large cytoskeletal proteins have primary roles in the maintenance of cytoskeletal integrity but are also associated with scaffolds of intermediate filaments and hemidesmosomal adhesion complexes mediating signalling pathways that regulate cellular growth, migration, invasion and differentiation as well as stress response. Abnormalities of plakins, and the closely related spectraplakins, result in diseases of the skin, striated muscle and nervous tissue. Their prevalence in epithelial cells suggests that plakins may play a role in epithelial ovarian cancer progression and recurrence. In this review article, we explore the roles of plakins, particularly plectin, periplakin and envoplakin in disease-states and cancers with emphasis on ovarian cancer. We discuss the potential role the plakin family of proteins play in regulating cancer cell growth, survival, migration, invasion and drug resistance. We highlight potential relationships between plakins, epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) and discuss how interaction of these processes may affect ovarian cancer progression, chemoresistance and ultimately recurrence. We propose that molecular changes in the expression of plakins leads to the transition of benign ovarian tumours to carcinomas, as well as floating cellular aggregates (commonly known as spheroids) in the ascites microenvironment, which may contribute to the sustenance and progression of the disease. In this review, attempts have been made to understand the crucial changes in plakin expression in relation to progression and recurrence of ovarian cancer.

show abstract

Section: Plakins In Cancermentioning

confidence: 99%

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Analysis of current trends in the studies of EGFR, its significance in oncological disorders, and in the develop ment of interventions for its therapeutic application demonstrates that as in the past most attention is paid to the ways of blocking EGFR mediated signaling. However, it has been increasingly evident that approach es combining EGFR overexpression and its alteration with the agents affecting cancer cells primarily by damag ing their activity deserved much attention [93,236,237]. Along with the traditional widely used approaches involv ing concurrent use of several therapeutic agents, multi functional systems have been developed.…”

Section: Concluding Remarks: Current Trends and Perspectivesmentioning

confidence: 99%

Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

Rosenkranz

Slastnikova

2020

Biochemistry Moscow

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is an integral surface protein mediating cellular response to a number of growth factors. Its overexpression and increased activation due to mutations is one of the most common traits of many types of cancer. Development and clinical use of the agents, which block EGFR activation, became a prime example of the personalized targeted medicine. However, despite the obvious success in this area, cancer cure remains unattainable in most cases. Because of that, as well as the result of the search for possible ways to overcome the difficulties of treatment, a huge number of new treatment methods relying on the use of EGFR overexpression and its changes to destroy cancer cells. Modern data on the structure, functioning, and intracellular transport of EGFR, its natural ligands, as well as signaling cascades triggered by the EGFR activation, peculiarities of the EGFR expression and activation in oncological disorders, as well as applied therapeutic approaches aimed at blocking EGFR signaling pathway are summarized and analyzed in this review. Approaches to the targeted delivery of various chemotherapeutic agents, radionuclides, immunotoxins, photosensitizers, as well as the prospects for gene therapy aimed at cancer cells with EGFR overexpression are reviewed in detail. It should be noted that increasing attention is being paid nowadays to the development of multifunctional systems, either carrying several different active agents, or possessing several environment-dependent transport functions. Potentials of the systems based on receptor-mediated endocytosis of EGFR and their possible advantages and limitations are discussed.

show abstract

“…Interestingly, PGRMC1 has been shown to bind and stabilize EGFR [ 17 ]. This is significant because EGFR overexpression has been observed in multiple tumor tissues and is associated with overall poor prognosis [ 130 , 131 , 132 , 133 ]. Activation of EGFR has been associated with increased proliferation, metastasis and angiogenesis [ 134 ].…”

Section: Non-classical P4 Signaling In Breast Cancermentioning

confidence: 99%

Classical and Non-Classical Progesterone Signaling in Breast Cancers

Pedroza

Subramani

Lakshmanaswamy

2020

Cancers

View full text Add to dashboard Cite

Much emphasis is placed on estrogen (E2) and estrogen receptor (ER) signaling as most research is focused on understanding E2 and ER’s ability to enhance proliferative signals in breast cancers. Progesterone (P4) is important for normal mammary gland development, function and menstrual control. However, P4 and its receptors (PRs) in breast cancer etiology continue to be understudied and its role in breast cancer remains controversial. The Women’s Health Initiative (WHI) clinical trial clearly demonstrated the importance of progestogens in breast cancer development. P4 has historically been associated with classical-signaling through nuclear receptors, however non-classical P4 signaling via membrane receptors has been described. Progestogens have the ability to bind to nuclear and membrane receptors and studies have demonstrated that both can promote breast cancer cell proliferation and breast tumor growth. In this review, we attempt to understand the classical and non-classical signaling role of P4 in breast cancers because both nuclear and membrane receptors could become viable therapeutic options for breast cancer patients.

show abstract

<p>Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles</p>

Cited by 47 publications

References 79 publications

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

Classical and Non-Classical Progesterone Signaling in Breast Cancers

Contact Info

Product

Resources

About